Eisai Wins FDA Approval For Novel, Once-Daily Seizure Drug Fycompa
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.
You may also be interested in...
Eisai Asks U.S. Court Of Appeals To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
Eisai says the U.S. Drug Enforcement Administration scheduling delay – 10 months after U.S. FDA approval and seven months after the U.S. Department of Health and Human Services submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.
Eisai Asks Court To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
Eisai says DEA’s scheduling delay – 10 months after FDA approval and seven months after HHS submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.
German Joy For Pharma As Drug Discount Prices Stay Hidden
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.